Shanghai Henlius Biotech, Inc.

Research Shanghai Henlius Biotech, Inc. (2696.HK) on Bullrun: market cap HKD 28.00B, P/E 29.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker2696.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 28.00B
P/E29.2
Financial periodFY2025
RevenueCNY 6.67B
Revenue growth16.5%
Net incomeCNY 827.04M
Free cash flowCNY 105.88M
Gross margin74.8%

Valuation Snapshot

latest market cap is HKD 28.00B; P/E is 29.2.

Peer valuation comparison

Latest P/E is 29.18x versus a Healthcare sector median of 21.69x (34.5% above).

Latest P/E is 29.18x versus a China median of 16.26x (79.4% above).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 6.67B	CNY 827.04M	CNY 105.88M	74.8%	1.51	CNY 772.21M	CNY 3.60B	CNY 3.96B
FY2024	CNY 5.72B	CNY 820.47M	CNY 404.68M	73.1%	1.51	CNY 772.96M	CNY 3.65B	CNY 3.01B
FY2023	CNY 5.39B	CNY 546.02M	CNY 36.48M	72.6%	1	CNY 987.67M	CNY 4.09B	CNY 2.19B
FY2022	CNY 3.21B	-CNY 695.26M	-CNY 383.67M	73.7%	-1.28	CNY 680.48M	CNY 3.68B	CNY 1.64B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 28.00B	29.2	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is Shanghai Henlius Biotech, Inc.'s market cap?

Shanghai Henlius Biotech, Inc.'s market capitalization is HKD 28.00B.

What is Shanghai Henlius Biotech, Inc.'s P/E ratio?

Shanghai Henlius Biotech, Inc.'s price-to-earnings (P/E) ratio is 29.2.

What does Shanghai Henlius Biotech, Inc. do?

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.